FDA Approvals, Stock Price Updates, and Financial Results Release - Analyst Notes on Pfizer, Actavis, Pharmacyclics, Mallinckrodt and Salix Pharmaceuticals

NEW YORK, May 16, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Pfizer Inc. (NYSE: PFE), Actavis plc (NYSE: ACT), Pharmacyclics, Inc. (NASDAQ: PCYC), Mallinckrodt PLC (NYSE: MNK) and Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2541-100free.

--
Pfizer Inc. Analyst Notes
On May 13, 2014, stocks of Pfizer Inc. (Pfizer) gained 0.24% to close trading at $29.20 per share. Over the past month of trading, Pfizer's stocks have lost 2.20% while the S&P 500 has gained 4.5% over the same duration. The full analyst notes on Pfizer are available to download free of charge at:

http://www.analystsreview.com/2541-PFE-16May2014.pdf

--
Actavis plc Analyst Notes
On May 13, 2014, Actavis plc (Actavis) reported that the U.S. Food and Drug Administration has given its final approval on the Company's Abbreviated New Drug Application for a generic version of Mallinckrodt Inc.'s Exalgo® (Hydromorphone Hydrochloride Extended-release Tablets 8 mg, 12 mg and 16 mg). Exalgo® is indicated for the management of moderate to severe pain in opioid tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time. Actavis stated that it plans to start shipping its product shortly and believes that, under applicable Hatch Waxman rules, it may be entitled to marketing exclusivity. The full analyst notes on Actavis are available to download free of charge at:

http://www.analystsreview.com/2541-ACT-16May2014.pdf

--
Pharmacyclics, Inc. Analyst Notes
On May 13, 2014, shares of Pharmacyclics, Inc. (Pharmacyclics) closed trading at $100.32, indicating a 1.59% increase. Over the last one month, Pharmacyclics' shares have gained 16.5%, outshining the Nasdaq Composite which has also gained 3.25% over the same time period. The full analyst notes on Pharmacyclics are available to download free of charge at:

http://www.analystsreview.com/2541-PCYC-16May2014.pdf

--
Mallinckrodt PLC Analyst Notes
On May 12, 2014, Mallinckrodt PLC (Mallinckrodt), together with Questcor Pharmaceuticals, Inc. (Questcor), jointly announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (HSR), in connection with the Company's proposed acquisition of Questcor (as announced on April 7, 2014), was terminated by the United States Federal Trade Commission on May 9, 2014. The Company stated that the early termination of the HSR waiting period satisfies one of the conditions to the proposed acquisition which remains subject to other customary closing conditions, including approval by the shareholders of both Companies. The transaction is currently expected to be completed in Q3 2014. The full analyst notes on Mallinckrodt are available to download free of charge at:

http://www.analystsreview.com/2541-MNK-16May2014.pdf

--
Salix Pharmaceuticals, Ltd. Analyst Notes
On May 8, 2014, Salix Pharmaceuticals, Ltd. (Salix Pharmaceuticals) announced its Q1 2014 results (which includes the impact of the Santarus acquisition finalized on January 2, 2014). Q1 2014 net product revenues rose 89.7% YoY to $384.4 million, while EBITDA increased 114.1% YoY to $149.2 million. For the quarter, the Company posted a net loss of $43.9 million or $0.69 loss per share, compared with net income of $22.4 million or $0.35 per diluted share in Q1 2013. The full analyst notes on Salix Pharmaceuticals are available to download free of charge at:

http://www.analystsreview.com/2541-SLXP-16May2014.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED